[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbf1Tnl0DLAFjTbtPjQv65F1ejEjjE2JnnUS_mQcyYmE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":29,"phaseBuckets":35,"rows":42},"Ochsner Health System",[4],56,false,6,2,4140,30,[13,15,17,19,21,23,25,27],{"name":14,"count":9},"Dementia",{"name":16,"count":9},"Neuroendocrine Carcinoma",{"name":18,"count":9},"Normal Healthy Volunteers Without Chronic Medical Conditions",{"name":20,"count":9},"Coronary Artery Disease",{"name":22,"count":9},"Cirrhosis, Liver",{"name":24,"count":9},"Emergence Delirium",{"name":26,"count":9},"Strabismus",{"name":28,"count":9},"Orthopedic Disorder",[30],{"nctId":31,"briefTitle":32,"date":33,"intervention":34},"NCT06613191","Colonoscopy and Antiplatelet Therapy Trial","2025-12-31","Aspirin",[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,70,88,126,153,180,198,223,241,266,284,311,329,355,379,409,440,466,492,510,535,560,604,632,657,675,699,725,743,767,791,818],{"intervention":34,"totalTrials":44,"cells":45},1,{"EARLY_PHASE1":46,"PHASE1":49,"PHASE2":51,"PHASE3":53,"PHASE4":55,"NA":68},{"trials":47,"activeCount":48},[],0,{"trials":50,"activeCount":48},[],{"trials":52,"activeCount":48},[],{"trials":54,"activeCount":48},[],{"trials":56,"activeCount":44,"soonestReadout":33},[57],{"nctId":31,"briefTitle":32,"status":58,"phases":59,"primaryCompletion":33,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":66},"NOT_YET_RECRUITING",[40],"2026-06-30","2024-10-01",100,[64,65],"Coronary Arterial Disease (CAD)","Peripheral Vascular Disease",[34,67],"P2Y12 inhibitor",{"trials":69,"activeCount":48},[],{"intervention":67,"totalTrials":44,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":86},{"trials":73,"activeCount":48},[],{"trials":75,"activeCount":48},[],{"trials":77,"activeCount":48},[],{"trials":79,"activeCount":48},[],{"trials":81,"activeCount":44,"soonestReadout":33},[82],{"nctId":31,"briefTitle":32,"status":58,"phases":83,"primaryCompletion":33,"completion":60,"start":61,"enrollment":62,"conditions":84,"interventions":85},[40],[64,65],[34,67],{"trials":87,"activeCount":48},[],{"intervention":89,"totalTrials":9,"cells":90},"Ropivacaine",{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":111,"NA":124},{"trials":92,"activeCount":48},[],{"trials":94,"activeCount":48},[],{"trials":96,"activeCount":48},[],{"trials":98,"activeCount":48},[99],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":110},"NCT04669145","Regional Anesthesia in Pediatric Orthopaedic Patients","COMPLETED",[38,39],"2024-04-22","2021-06-24",24,[108,109,28],"Anesthesia, Local","Anesthesia",[89],{"trials":112,"activeCount":48},[113],{"nctId":114,"briefTitle":115,"status":102,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT03921034","IPACK Nerve Block for Total Knee Arthroplasty",[40],"2018-01-23","2016-11-17",72,[121,109],"Arthropathy of Knee",[89,123],"Saline",{"trials":125,"activeCount":48},[],{"intervention":127,"totalTrials":44,"cells":128},"Slow Infusion of Rubidium-82",{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":151},{"trials":130,"activeCount":48},[],{"trials":132,"activeCount":48},[],{"trials":134,"activeCount":48},[],{"trials":136,"activeCount":48},[],{"trials":138,"activeCount":48},[139],{"nctId":140,"briefTitle":141,"status":102,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":150},"NCT05286593","3D PET Myocardial Blood Flow and Rb82 Infusion Profiles",[40],"2022-09-01","2022-09-30","2021-12-28",98,[18,20,148,149],"Cardiac Risk Factors","Myocardial Infarction",[127,127,127],{"trials":152,"activeCount":48},[],{"intervention":154,"totalTrials":44,"cells":155},"Ambrisentan Pill",{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":178},{"trials":157,"activeCount":48},[],{"trials":159,"activeCount":48},[],{"trials":161,"activeCount":48},[],{"trials":163,"activeCount":48},[],{"trials":165,"activeCount":48},[166],{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":48,"conditions":173,"interventions":176},"NCT03309592","Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension","WITHDRAWN",[40],"2018-11-01","2017-10-12",[174,175,22],"Portopulmonary Hypertension","Pulmonary Hypertension",[154,177],"Tadalafil Pill",{"trials":179,"activeCount":48},[],{"intervention":177,"totalTrials":44,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":196},{"trials":183,"activeCount":48},[],{"trials":185,"activeCount":48},[],{"trials":187,"activeCount":48},[],{"trials":189,"activeCount":48},[],{"trials":191,"activeCount":48},[192],{"nctId":167,"briefTitle":168,"status":169,"phases":193,"primaryCompletion":171,"completion":171,"start":172,"enrollment":48,"conditions":194,"interventions":195},[40],[174,175,22],[154,177],{"trials":197,"activeCount":48},[],{"intervention":199,"totalTrials":44,"cells":200},"Propofol",{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":221},{"trials":202,"activeCount":48},[],{"trials":204,"activeCount":48},[],{"trials":206,"activeCount":48},[],{"trials":208,"activeCount":48},[],{"trials":210,"activeCount":48},[211],{"nctId":212,"briefTitle":213,"status":102,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":119,"conditions":217,"interventions":219},"NCT02578862","Total Intravenous Anesthesia in Sinus Surgery",[40],"2018-06","2015-07",[218],"Advanced Chronic Rhinosinusitis",[199,220],"Sevoflurane",{"trials":222,"activeCount":48},[],{"intervention":220,"totalTrials":44,"cells":224},{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":233,"NA":239},{"trials":226,"activeCount":48},[],{"trials":228,"activeCount":48},[],{"trials":230,"activeCount":48},[],{"trials":232,"activeCount":48},[],{"trials":234,"activeCount":48},[235],{"nctId":212,"briefTitle":213,"status":102,"phases":236,"primaryCompletion":215,"completion":215,"start":216,"enrollment":119,"conditions":237,"interventions":238},[40],[218],[199,220],{"trials":240,"activeCount":48},[],{"intervention":242,"totalTrials":44,"cells":243},"Furosemide plus Chlorothiazide",{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":264},{"trials":245,"activeCount":48},[],{"trials":247,"activeCount":48},[],{"trials":249,"activeCount":48},[],{"trials":251,"activeCount":48},[],{"trials":253,"activeCount":48},[254],{"nctId":255,"briefTitle":256,"status":169,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":48,"conditions":260,"interventions":262},"NCT05840536","Combination Diuretic Therapy for Acute Decompensated Heart Failure",[40],"2015-10","2014-05",[261],"Acute Decompensated Heart Failure",[242,263],"Furosemide",{"trials":265,"activeCount":48},[],{"intervention":263,"totalTrials":44,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":282},{"trials":269,"activeCount":48},[],{"trials":271,"activeCount":48},[],{"trials":273,"activeCount":48},[],{"trials":275,"activeCount":48},[],{"trials":277,"activeCount":48},[278],{"nctId":255,"briefTitle":256,"status":169,"phases":279,"primaryCompletion":258,"completion":258,"start":259,"enrollment":48,"conditions":280,"interventions":281},[40],[261],[242,263],{"trials":283,"activeCount":48},[],{"intervention":285,"totalTrials":44,"cells":286},"Exparel Injectable Product",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":309},{"trials":288,"activeCount":48},[],{"trials":290,"activeCount":48},[],{"trials":292,"activeCount":48},[],{"trials":294,"activeCount":48},[],{"trials":296,"activeCount":48},[297],{"nctId":298,"briefTitle":299,"status":102,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT04781075","Modified TAP (Transverse Abdominis Plane) Block in Colorectal Surgery",[40],"2020-12-31","2021-07-31","2017-12-01",76,[306],"Pain, Postoperative",[285,308],"Bupivacaine",{"trials":310,"activeCount":48},[],{"intervention":308,"totalTrials":44,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":327},{"trials":314,"activeCount":48},[],{"trials":316,"activeCount":48},[],{"trials":318,"activeCount":48},[],{"trials":320,"activeCount":48},[],{"trials":322,"activeCount":48},[323],{"nctId":298,"briefTitle":299,"status":102,"phases":324,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":325,"interventions":326},[40],[306],[285,308],{"trials":328,"activeCount":48},[],{"intervention":330,"totalTrials":44,"cells":331},"intravenous NAC",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":340,"NA":353},{"trials":333,"activeCount":48},[],{"trials":335,"activeCount":48},[],{"trials":337,"activeCount":48},[],{"trials":339,"activeCount":48},[],{"trials":341,"activeCount":48},[342],{"nctId":343,"briefTitle":344,"status":345,"phases":346,"primaryCompletion":347,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":352},"NCT00939913","Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy","UNKNOWN",[40],"2010-05","2007-01",400,[351],"Nephropathy",[330],{"trials":354,"activeCount":48},[],{"intervention":356,"totalTrials":44,"cells":357},"Retapamulin",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":377},{"trials":359,"activeCount":48},[],{"trials":361,"activeCount":48},[],{"trials":363,"activeCount":48},[],{"trials":365,"activeCount":48},[],{"trials":367,"activeCount":48},[368],{"nctId":369,"briefTitle":370,"status":169,"phases":371,"primaryCompletion":372,"completion":372,"start":373,"enrollment":48,"conditions":374,"interventions":376},"NCT00856089","Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization",[40],"2009-10","2009-05",[375],"Methicillin-resistant Staphylococcus Aureus",[356],{"trials":378,"activeCount":48},[],{"intervention":380,"totalTrials":44,"cells":381},"Xylitol",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":405,"NA":407},{"trials":383,"activeCount":48},[],{"trials":385,"activeCount":48},[],{"trials":387,"activeCount":48},[],{"trials":389,"activeCount":48},[390],{"nctId":391,"briefTitle":392,"status":102,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":44,"conditions":396,"interventions":404},"NCT03229551","Xylitol for Chronic Sinusitis",[38,39],"2018-07-16","2018-03-01",[397,398,399,400,401,402,403],"Chronic Rhinosinusitis","Rhinosinusitis","Sinusitis","Drain Sinus","Endoscopic Sinus Surgery","Biofilms","Bacterial Overgrowth",[380,123],{"trials":406,"activeCount":48},[],{"trials":408,"activeCount":48},[],{"intervention":410,"totalTrials":44,"cells":411},"68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":413,"activeCount":48},[],{"trials":415,"activeCount":48},[],{"trials":417,"activeCount":48},[418],{"nctId":419,"briefTitle":420,"status":345,"phases":421,"primaryCompletion":422,"start":423,"enrollment":424,"conditions":425,"interventions":433},"NCT02038738","68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors",[37,38],"2019-03","2014-03",250,[426,427,428,16,429,430,431,432],"Neuroendocrine","Neuroendocrine Tumor","Neuroendocrine Cancer","Carcinoid","Carcinoid Tumor","Islet Cell Tumor","Apudoma",[410],{"trials":435,"activeCount":48},[],{"trials":437,"activeCount":48},[],{"trials":439,"activeCount":48},[],{"intervention":441,"totalTrials":44,"cells":442},"RBX7455",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":444,"activeCount":48},[],{"trials":446,"activeCount":48},[],{"trials":448,"activeCount":48},[449],{"nctId":450,"briefTitle":451,"status":452,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT04155099","Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy","TERMINATED",[38],"2023-07-30","2021-03-01",5,[458,22],"Hepatic Encephalopathy",[441],{"trials":461,"activeCount":48},[],{"trials":463,"activeCount":48},[],{"trials":465,"activeCount":48},[],{"intervention":467,"totalTrials":44,"cells":468},"HyperAcute vaccine",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":486,"PHASE4":488,"NA":490},{"trials":470,"activeCount":48},[],{"trials":472,"activeCount":48},[],{"trials":474,"activeCount":48},[475],{"nctId":476,"briefTitle":477,"status":345,"phases":478,"primaryCompletion":479,"completion":480,"start":481,"enrollment":11,"conditions":482,"interventions":484},"NCT00746746","A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma",[38],"2010-06","2011-06","2008-06",[483],"Melanoma",[467,485],"Pegylated Interferon-Alpha 2b",{"trials":487,"activeCount":48},[],{"trials":489,"activeCount":48},[],{"trials":491,"activeCount":48},[],{"intervention":485,"totalTrials":44,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":504,"PHASE4":506,"NA":508},{"trials":495,"activeCount":48},[],{"trials":497,"activeCount":48},[],{"trials":499,"activeCount":48},[500],{"nctId":476,"briefTitle":477,"status":345,"phases":501,"primaryCompletion":479,"completion":480,"start":481,"enrollment":11,"conditions":502,"interventions":503},[38],[483],[467,485],{"trials":505,"activeCount":48},[],{"trials":507,"activeCount":48},[],{"trials":509,"activeCount":48},[],{"intervention":511,"totalTrials":44,"cells":512},"treprostinil dienthanolmine sustained release",{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":529,"PHASE4":531,"NA":533},{"trials":514,"activeCount":48},[],{"trials":516,"activeCount":48},[],{"trials":518,"activeCount":48},[519],{"nctId":520,"briefTitle":521,"status":102,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":528},"NCT00651885","Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure",[38],"2010-12","2008-03",7,[527],"Critical Limb Ischemia",[511],{"trials":530,"activeCount":48},[],{"trials":532,"activeCount":48},[],{"trials":534,"activeCount":48},[],{"intervention":536,"totalTrials":44,"cells":537},"Pembrolizumab",{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":554,"PHASE4":556,"NA":558},{"trials":539,"activeCount":48},[],{"trials":541,"activeCount":48},[],{"trials":543,"activeCount":48},[544],{"nctId":545,"briefTitle":546,"status":169,"phases":547,"primaryCompletion":548,"completion":548,"start":549,"enrollment":48,"conditions":550,"interventions":553},"NCT03901378","Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma",[38],"2021-01-21","2019-10-02",[16,551,552],"Large Cell Neuroendocrine Carcinoma of the Lung","High Grade Neuroendocrine Carcinoma, Any Site",[536],{"trials":555,"activeCount":48},[],{"trials":557,"activeCount":48},[],{"trials":559,"activeCount":48},[],{"intervention":561,"totalTrials":562,"cells":563},"saline",4,{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":576,"NA":582},{"trials":565,"activeCount":48},[],{"trials":567,"activeCount":48},[],{"trials":569,"activeCount":48},[],{"trials":571,"activeCount":48},[572],{"nctId":391,"briefTitle":392,"status":102,"phases":573,"primaryCompletion":394,"completion":394,"start":395,"enrollment":44,"conditions":574,"interventions":575},[38,39],[397,398,399,400,401,402,403],[380,123],{"trials":577,"activeCount":48},[578],{"nctId":114,"briefTitle":115,"status":102,"phases":579,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":580,"interventions":581},[40],[121,109],[89,123],{"trials":583,"activeCount":48},[584,595],{"nctId":585,"briefTitle":586,"status":452,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT00778063","Study Using Dexmedetomidine to Decreases Emergence Delirium in Pediatric Patients",[41],"2013-03","2008-09",40,[592],"Otitis Media",[594,561],"dexmedetomidine",{"nctId":596,"briefTitle":597,"status":169,"phases":598,"primaryCompletion":479,"completion":479,"start":599,"enrollment":48,"conditions":600,"interventions":602},"NCT00802646","The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers",[41],"2009-06",[601],"Vaginal Delivery",[561,603],"fentanyl\u002Fbupivacaine\u002Fepinephrine",{"intervention":594,"totalTrials":9,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":607,"activeCount":48},[],{"trials":609,"activeCount":48},[],{"trials":611,"activeCount":48},[],{"trials":613,"activeCount":48},[],{"trials":615,"activeCount":48},[],{"trials":617,"activeCount":48},[618,622],{"nctId":585,"briefTitle":586,"status":452,"phases":619,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":620,"interventions":621},[41],[592],[594,561],{"nctId":623,"briefTitle":624,"status":102,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":630},"NCT03779282","KETODEX for Emergence Delirium in Children Undergoing Outpatient Strabismus Surgery",[],"2018-09-15","2018-02-15",90,[24,26],[631],"Dexmedetomidine",{"intervention":633,"totalTrials":44,"cells":634},"0.5% ropivacaine",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":643,"NA":645},{"trials":636,"activeCount":48},[],{"trials":638,"activeCount":48},[],{"trials":640,"activeCount":48},[],{"trials":642,"activeCount":48},[],{"trials":644,"activeCount":48},[],{"trials":646,"activeCount":48},[647],{"nctId":648,"briefTitle":649,"status":169,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":48,"conditions":653,"interventions":655},"NCT01217580","Pain Relief Study of Ultrasound Guided Transverse Abdominis Plane(TAP)Block",[41],"2011-10","2010-10",[654],"Cesarean Section",[633,656],"0.9% sodium chloride",{"intervention":656,"totalTrials":44,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":660,"activeCount":48},[],{"trials":662,"activeCount":48},[],{"trials":664,"activeCount":48},[],{"trials":666,"activeCount":48},[],{"trials":668,"activeCount":48},[],{"trials":670,"activeCount":48},[671],{"nctId":648,"briefTitle":649,"status":169,"phases":672,"primaryCompletion":651,"completion":651,"start":652,"enrollment":48,"conditions":673,"interventions":674},[41],[654],[633,656],{"intervention":676,"totalTrials":44,"cells":677},"transdermal nicotine patch",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":688},{"trials":679,"activeCount":48},[],{"trials":681,"activeCount":48},[],{"trials":683,"activeCount":48},[],{"trials":685,"activeCount":48},[],{"trials":687,"activeCount":48},[],{"trials":689,"activeCount":48},[690],{"nctId":691,"briefTitle":692,"status":169,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":48,"conditions":696,"interventions":698},"NCT00775749","Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and\u002For Vomiting (PONV)",[41],"2012-04","2009-04",[697],"Postoperative Nausea and Vomiting",[676],{"intervention":700,"totalTrials":44,"cells":701},"Intravenous Solution",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":703,"activeCount":48},[],{"trials":705,"activeCount":48},[],{"trials":707,"activeCount":48},[],{"trials":709,"activeCount":48},[],{"trials":711,"activeCount":48},[],{"trials":713,"activeCount":48},[714],{"nctId":715,"briefTitle":716,"status":102,"phases":717,"primaryCompletion":718,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT04817722","Hydration During Thoracic Surgery",[],"2016-01-31","2016-06-01","2014-12-12",222,[723],"Hospital Length of Stay; Adverse Events",[700],{"intervention":603,"totalTrials":44,"cells":726},{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":735,"NA":737},{"trials":728,"activeCount":48},[],{"trials":730,"activeCount":48},[],{"trials":732,"activeCount":48},[],{"trials":734,"activeCount":48},[],{"trials":736,"activeCount":48},[],{"trials":738,"activeCount":48},[739],{"nctId":596,"briefTitle":597,"status":169,"phases":740,"primaryCompletion":479,"completion":479,"start":599,"enrollment":48,"conditions":741,"interventions":742},[41],[601],[561,603],{"intervention":744,"totalTrials":44,"cells":745},"FFR Measurement with IV Adenoscan® then with Regadenoson",{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":747,"activeCount":48},[],{"trials":749,"activeCount":48},[],{"trials":751,"activeCount":48},[],{"trials":753,"activeCount":48},[],{"trials":755,"activeCount":48},[],{"trials":757,"activeCount":48},[758],{"nctId":759,"briefTitle":760,"status":102,"phases":761,"primaryCompletion":259,"completion":762,"start":763,"enrollment":764,"conditions":765,"interventions":766},"NCT01482169","Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)",[41],"2014-09","2012-03",48,[20],[744],{"intervention":768,"totalTrials":44,"cells":769},"Methadone",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":771,"activeCount":48},[],{"trials":773,"activeCount":48},[],{"trials":775,"activeCount":48},[],{"trials":777,"activeCount":48},[],{"trials":779,"activeCount":48},[],{"trials":781,"activeCount":48},[782],{"nctId":783,"briefTitle":784,"status":102,"phases":785,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":790},"NCT03778372","Methadone for Emergence Delirium in Children Undergoing Outpatient Strabismus Surgery",[],"2020-12-13","2019-01-01",55,[24,26],[768],{"intervention":792,"totalTrials":44,"cells":793},"Antibiotics",{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":795,"activeCount":48},[],{"trials":797,"activeCount":48},[],{"trials":799,"activeCount":48},[],{"trials":801,"activeCount":48},[],{"trials":803,"activeCount":48},[],{"trials":805,"activeCount":48},[806],{"nctId":807,"briefTitle":808,"status":102,"phases":809,"primaryCompletion":810,"completion":810,"start":811,"enrollment":812,"conditions":813,"interventions":817},"NCT03644966","Probiotics and Multi-Drug Resistant Urinary Tract Infection",[41],"2022-12-15","2018-07-05",25,[814,815,816],"Urinary Tract Infections","Recurrent UTI","Antibiotic Resistant Infection",[792],{"intervention":819,"totalTrials":44,"cells":820},"Vancomycin",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":822,"activeCount":48},[],{"trials":824,"activeCount":48},[],{"trials":826,"activeCount":48},[],{"trials":828,"activeCount":48},[],{"trials":830,"activeCount":48},[],{"trials":832,"activeCount":48},[833],{"nctId":834,"briefTitle":835,"status":169,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":48,"conditions":839,"interventions":842},"NCT03046901","Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients",[41],"2019-02-25","2016-12-07",[840,841],"Primary Sclerosing Cholangitis","Post- Orthotopic Liver Transplantation",[819]]